Article

Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

Author(s):

OT Staff Reports

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Advanced therapies for retinal vascular diseases
December 23rd 2024

Advanced therapies for retinal vascular diseases

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA
December 17th 2024

The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA

© 2024 MJH Life Sciences

All rights reserved.